ClinConnect ClinConnect Logo
Search / Trial NCT06913764

First- or Second- Class Compression Hosiery After Endovenous Laser With Sclerotherapy and Ambulatory Phlebectomy

Launched by MOSCOW CITY HOSPITAL NAMED AFTER A.K. ERAMISHANTSEV · Mar 31, 2025

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Varicose Veins Varicose Disease Compression Therapy Medical Compression Stockings Mcs Venous Disease Veins Vein Surgery Elastic Hosiery Compression Hosiery Endovenous Laser Endovenous Laser Ablation Thermal Ablation Sclerotherapy Microsclerotherapy Phlebectomy Ambulatory Phlebectomy Elastic Compression

ClinConnect Summary

This clinical trial is studying how different levels of compression hosiery can help patients after a specific vein treatment. The researchers want to see if using first-class compression stockings, which are easier to put on and more comfortable, will help patients stick to their treatment plan better than second-class stockings. The trial involves patients who have varicose veins in their legs and are receiving a procedure called endovenous laser ablation, along with sclerotherapy and phlebectomy, to treat these veins.

To be eligible for this study, participants must be at least 18 years old and have varicose veins classified as C2-C5, which means they have noticeable symptoms but not severe complications. They should be undergoing the recommended vein treatment and must have given their consent to join the study. Patients who have a history of certain vein problems or other specific medical conditions may not be able to participate. Those who join the study can expect to wear either first-class or second-class compression stockings for two weeks after their procedure, and the researchers will monitor how well these stockings work for them.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥18 years
  • Varicose veins of the lower extremities (CEAP classification C2-C5)
  • Varicose disease in the great saphenous vein (GSV) and its tributaries
  • Planned endovenous laser ablation of the GSV trunk with concomitant combined sclerotherapy and phlebectomy of tributaries
  • Technical success of intervention (complete ablation of the GSV)
  • Signed informed consent for study participation
  • Exclusion Criteria:
  • Primary reflux outside the GSV trunk
  • History of or acute deep vein thrombosis
  • Deep vein insufficiency
  • GSV recanalization post-intervention
  • Clinical class C6 of chronic venous disease (CVD) according to CEAP classification
  • Contraindications or limitations for prolonged compression therapy, including but not limited to chronic arterial diseases of the lower extremities (any severity), skin diseases
  • Pathological conditions of lower limbs causing non-venous pain
  • Use of vasoactive medications within 1 month before/after surgery
  • Refusal to participate in the study

About Moscow City Hospital Named After A.K. Eramishantsev

Moscow City Hospital named after A.K. Eramishantsev is a leading healthcare institution dedicated to advancing medical research and patient care. As a prominent clinical trial sponsor, the hospital is committed to conducting innovative studies that contribute to the development of new therapies and improve treatment outcomes. With a team of experienced medical professionals and researchers, the hospital fosters a collaborative environment to ensure high standards of ethics, safety, and scientific rigor in all clinical trials. Its strategic location in Moscow allows for diverse patient recruitment and engagement, further enhancing the impact of its research initiatives.

Locations

Moscow, , Russian Federation

Moscow, , Russian Federation

Patients applied

0 patients applied

Trial Officials

Hovsep P. Manjikian, MD

Study Chair

Moscow City Hospital named after A.K. Eramishantsev

Boris Danelian, MD

Principal Investigator

Moscow City Hospital named after A.K. Eramishantsev

Hovsep Manjikyan, MD

Principal Investigator

Moscow City Hospital named after A.K. Eramishantsev

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported